Abstract
We have read with interest the recent article,1 in which the authors aimed to compare four test to assess inhibition of platelet function by clopidogrel in stable coronary disease patients. They demonstrate that the results of each test are not equivalent, being highly test-specific. The identification of patients with insufficient platelet inhibition varied greatly and correlations between the tests were poor. The idea of tailoring antiplatelet therapy is a promising tool to improve the outcomes of patients but we must not forget that …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
